BioVie Inc. (BIVI) Discusses Bezisterim’s Mechanism of Action and Its Potential in Addressing Parkinson’s Disease Pathology May 7, 2026 2:00 PM EDT
Company Participants
Cuong Viet Do – President, CEO & Director
Joseph Palumbo – Executive VP of R&D and Chief Medical Officer
Clarence Ahlem – Senior Vice President of Operations
Conference Call Participants
Suzanne de la Monte
Presentation
Operator
Good afternoon, and welcome to the BioVie Virtual KOL event. [Operator Instructions]
As a reminder, this call is being recorded, and a replay will be made available on the BioVie website following the conclusion of the event. Please refer to this slide about forward-looking statements, which describe the disclaimers and risk factors related to such statements and consult BioVie’s public filings made with the Securities and Exchange Commission that can be found at www.sec.gov. With that, I’d like to now turn the call over to Cuong Do, Chief Executive Officer of BioVie. Please go ahead, Cuong.
Cuong Viet Do
President, CEO & Director
Thank you, Serra. Thank you, everyone, for joining today. My name is Cuong Do. I’m the President and CEO of BioVie. I’d just like to take a few minutes to give everyone an update on where we stand with our 2 clinical trials. Our first trial, of course, is in Parkinson’s. That trial is nearly complete. The last patient has come in for his last visit. So our team is working through the study closeout process right now to basically go through all the data to clean up the data and so forth.
But most importantly, we needed to wait for the biomarker data to come back in. We are hoping to have everything in and analyzed by the end of this quarter, but it may slip into next quarter depending on how long it takes for us to get
